These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22999992)

  • 1. An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR).
    Yu D; Mattern DL; Forman BM
    Steroids; 2012 Nov; 77(13):1335-8. PubMed ID: 22999992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
    Pellicciari R; Fiorucci S; Camaioni E; Clerici C; Costantino G; Maloney PR; Morelli A; Parks DJ; Willson TM
    J Med Chem; 2002 Aug; 45(17):3569-72. PubMed ID: 12166927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
    J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
    Costantino G; Macchiarulo A; Entrena-Guadix A; Camaioni E; Pellicciari R
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1865-8. PubMed ID: 12749886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice.
    Lívero FA; Stolf AM; Dreifuss AA; Bastos-Pereira AL; Chicorski R; de Oliveira LG; de Souza CE; Fabossi IA; Rabitto IS; Gremski LH; Henneberg R; Telles JE; Oude Elferink RP; Acco A
    Chem Biol Interact; 2014 Jun; 217():19-27. PubMed ID: 24713361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
    Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in the ligands and their complex structures of farnesoid X receptor].
    Li WH; Fu J; Zheng MY; Liu GX; Tang Y
    Yao Xue Xue Bao; 2012 Jun; 47(6):704-15. PubMed ID: 22919716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.
    Sepe V; Ummarino R; D'Auria MV; Chini MG; Bifulco G; Renga B; D'Amore C; Debitus C; Fiorucci S; Zampella A
    J Med Chem; 2012 Jan; 55(1):84-93. PubMed ID: 22126372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
    Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
    Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
    Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
    Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β.
    Noh K; Kim YM; Kim YW; Kim SG
    Drug Metab Dispos; 2011 Aug; 39(8):1451-9. PubMed ID: 21596890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.
    Miyazaki-Anzai S; Levi M; Kratzer A; Ting TC; Lewis LB; Miyazaki M
    Circ Res; 2010 Jun; 106(12):1807-17. PubMed ID: 20431060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands.
    Di Leva FS; Festa C; D'Amore C; De Marino S; Renga B; D'Auria MV; Novellino E; Limongelli V; Zampella A; Fiorucci S
    J Med Chem; 2013 Jun; 56(11):4701-17. PubMed ID: 23656455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
    Roda A; Pellicciari R; Gioiello A; Neri F; Camborata C; Passeri D; De Franco F; Spinozzi S; Colliva C; Adorini L; Montagnani M; Aldini R
    J Pharmacol Exp Ther; 2014 Jul; 350(1):56-68. PubMed ID: 24784847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
    Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N
    Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and in vitro Profiling of Dual FXR/LTA4H Modulators.
    Schierle S; Brunst S; Helmstädter M; Ebert R; Kramer JS; Steinhilber D; Proschak E; Merk D
    ChemMedChem; 2021 Aug; 16(15):2366-2374. PubMed ID: 33856122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid.
    He XL; Wang LT; Gu XZ; Xiao JX; Qiu WW
    Steroids; 2018 Dec; 140():173-178. PubMed ID: 30389306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.